| 1 |
Drug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration |
|
| | Ayse Sahaboglu,Maria Miranda,Denis Canjuga,Meltem Avci-Adali,Natalia Savytska,Enver Secer,Jessica Abigail Feria-Pliego,Gülru Kayik,Serdar Durdagi | | | Cellular and Molecular Life Sciences. 2019; | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
PARP inhibition by olaparib alleviates chronic asthma-associated remodeling features via modulating inflammasome signaling in mice |
|
| | Gurupreet S. Sethi,Sukriti Sharma,Amarjit S. Naura | | | IUBMB Life. 2019; | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
PARP-1 inhibition alleviates diabetic cardiac complications in experimental animals |
|
| | Esraa Zakaria,Hany El-Bassossy,Nabila El-Maraghi,Ahmed Fahmy,Abdelmonim Ali | | | European Journal of Pharmacology. 2016; | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Ex vivoprotective effects of nicotinamide and 3-aminobenzamide on rat synaptosomes treated with Aß(1-42) |
|
| | Ezgi Turunc Bayrakdar,Guliz Armagan,Yigit Uyanikgil,Lutfiye Kanit,Ersin Koylu,Ayfer Yalcin | | | Cell Biochemistry and Function. 2014; : n/a | | | [Pubmed] [Google Scholar] [DOI] | |
|
